99 citations
,
September 2007 in “The American journal of pathology” This study found that organ-cultured human scalp hair follicles can mimic chemotherapy-induced damage in vivo and serve as a model to explore molecular targets and protective agents for hair follicle preservation.
97 citations
,
September 2006 in “Pharmaceutical Research” This review discusses advances in protecting against chemotherapy-induced alopecia and reports no new clinical results; calcitriol and cyclosporine A emerged as promising agents in animal models with broader efficacy across multiple chemotherapy drugs.
159 citations
,
July 2006 in “Endocrine Reviews” This article discusses the influence of estrogens on hair follicle growth and metabolism, suggesting a significant role alongside androgens in hair growth control but reports no new clinical results.
106 citations
,
June 2005 in “Journal of Investigative Dermatology” This study defines classification criteria for hair follicle dystrophy using a mouse model of chemotherapy-induced alopecia, providing tools for standardized hair damage assessment.
44 citations
,
March 2004 in “Journal of Investigative Dermatology” This study observed that in vitro treatment of male frontotemporal scalp hair follicles with 17-β-estradiol stimulated hair shaft generation and hair matrix keratinocyte proliferation, suggesting potential anagen-prolonging effects.
76 citations
,
January 2004 in “Journal of Investigative Dermatology”
51 citations
,
December 2003 in “The FASEB Journal” This study reports that AS101 induced hair growth in mice and suggests potential for treating chemotherapy-induced alopecia in humans, which was observed in case report studies with three adolescents.
1 citations
,
January 2000 in “PubMed” The treatment slightly increased hair growth and was safe for most women.
1113 citations
,
August 1999 in “The New England Journal of Medicine” This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.
130 citations
,
December 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” In this study, different types of catagen in the C57BL/6 mouse model exhibited varying effects on hair follicle melanocytes and melanin distribution, with spontaneous and dexamethasone-induced catagen showing pigment incontinence, while cyclophosphamide-induced catagen retained dendritic melanocytes but increased ectopic melanin.
53 citations
,
October 1998 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that cyclophosphamide induced significant keratinocyte apoptosis in anagen hair follicles of mice, while topical calcitriol-analogs reduced this apoptosis, suggesting a protective effect against chemotherapy-induced alopecia.
36 citations
,
April 1994 in “PubMed” This study introduces a mouse model of cyclophosphamide-induced alopecia, which effectively replicates human chemotherapy-induced hair loss and can be pharmacologically manipulated to study hair regrowth patterns.
385 citations
,
November 1990 in “Journal of Cell Science” This study successfully grew and maintained human hair follicles in vitro, noting that TGF-β1 negatively affects growth, while EGF replicates hair-removal effects seen in animals.
7 citations
,
October 1974 in “PubMed” In this study, topical estrogens and corticosteroids were associated with decreased telogen rates in 52% of androgenetic alopecia patients, suggesting potential clinical improvement, though the role of corticosteroids remains unclear.